Skip to main content
Equibles

SIGHT · GENSIGHT BIOLOGICS · Financials

Use SIGHT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SIGHT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
0.0801 EUR -0.0036 (-4.30%) At close · Oct 5
Rebalance outlook locked
Market Cap
28.79M EUR
Shares
234.47M

Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.

Pull these statements through the financial statements API or MCP →

Browse captured authority reports and their original financial labels

Revenue
1.5M +18.4%
FY2024 Revenue FY2020–FY2024
Net Income
-14M +46.6%
FY2024 Net Income FY2020–FY2024
Operating Margin
-1054.2% +1289.6pp
FY2024 Operating Margin FY2020–FY2024
Operating Cash Flow
-12.94M +47.5%
FY2024 Operating Cash Flow FY2020–FY2024

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item FY2024 FY2023 FY2022 FY2021 FY2020
EUR 1.5M 1.27M 2.58M 5.28M 4.39M
EUR 12.37M 19.36M 19.34M 22.92M 22.39M
EUR 685K 7.95M 8M 5.51M 1.98M
EUR 5.39M 5.35M 5.36M 7.41M 8.01M
EUR -15.81M -29.7M -27.84M -28.13M -24.93M
EUR — 3.4M 3.67M 2.5M 9.71M
EUR 21K 0 5000 2000 2000
EUR -14M -26.22M -27.63M -28.62M -34.02M
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2021–FY2022: 498K in buybacks.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Current bonds issued, including current portion of noncurrent bonds 2024-12-31 EUR 6,973,000 ESEF Annual Report filed 2025-04-15
Current lease liabilities 2024-12-31 EUR 585,000 ESEF Annual Report filed 2025-04-15
Current portion of long-term borrowings 2024-12-31 EUR 6,341,000 ESEF Annual Report filed 2025-04-15
Noncurrent bonds issued 2024-12-31 EUR 0 ESEF Annual Report filed 2025-04-15
Noncurrent lease liabilities 2024-12-31 EUR 514,000 ESEF Annual Report filed 2025-04-15
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.